April 14, 2019 08:00 PM EDTUpdated May 30, 11:45 AM
R&D

Out­rac­ing 2 gi­ant ri­vals, J&J touts promis­ing PhI­II In­vokana da­ta as a game-chang­er for kid­ney dis­ease risks

John Carroll

Editor & Founder

In a race to ex­pand mar­ket share against two top ri­vals in the di­a­betes field, J&J just scored one in the win col­umn. And they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times